Hims & Hers vs Remedy Meds (2026): prices, structure, verdict

On tirzepatide, only Remedy Meds↗ has a rankable figure: $399 a month all-in; Hims & Hers↗ routes tirzepatide through brand channels without a single compounded cash price — its cost depends on coverage or the manufacturer programs (Zepbound vials $299–$449; Wegovy $349).

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, only Remedy Meds has a rankable figure: $299 a month all-in; Hims & Hers routes semaglutide through brand channels without a single compounded cash price — its cost depends on coverage or the manufacturer programs (Zepbound vials $299–$449; Wegovy $349).

§ Side by side

§ Each record, read aloud

The two records, condensed

Hims & Hers: the record, condensed

Hims & Hers routes tirzepatide through brand product — no single compounded cash figure exists to rank. The reference prices live one layer down: Zepbound (LillyDirect↗), $299–$449 a month cash, or whatever your insurance turns those numbers into.

On semaglutide, Hims & Hers is a brand channel rather than a priced product: it prescribes the FDA-approved medication, and what you pay depends on coverage or the manufacturer cash programs (Wegovy (NovoCare↗) at $199–$349).

Operationally at Hims & Hers: shipping included; commitment plan recurs; cancellation plan recurs until cancelled; pharmacy named (brand fulfillment; compounded program closed to new patients); states: 50 states; evidence no public price, captured 2026-08-05. The full record with source and archive links: the Hims & Hers page · visit Hims & Hers ↗

Remedy Meds: the record, condensed

Start with the load-bearing figure: $399 a month, all-in, is what Remedy Meds charges for tirzepatide at the 10 mg basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Remedy Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #15 of 17 verified programs, with the floor $184/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

On semaglutide, the number that matters at Remedy Meds is $299 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #19 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at Remedy Meds: shipping included; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Remedy Meds page · visit Remedy Meds ↗

§ Structure vs structure

Everything besides the price

Coverage: Hims & Hers publishes “50 states”; Remedy Meds publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: Hims & Hers names its network (brand fulfillment; compounded program closed to new patients); Remedy Meds does not, which shifts the burden of verification onto your intake questions.

Exit terms: Hims & Hers — plan recurs; plan recurs until cancelled. Remedy Meds — unknown; not published.

Evidence: Hims & Hers no public price (captured 2026-08-05); Remedy Meds third-party reported (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

§ If you move

Switching between Hims & Hers and Remedy Meds

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Hims & Hers: plan recurs until cancelled; Remedy Meds: not published) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings